Additional Relevant Details fibrocell logo AboutTechnologyPipeline & Clinical TrialsInvestorsPatients & Families News & EventsContact About Press Release Investors | Press Release View printer-friendly version Back Fibrocell Announces Last Patient Visit for Primary Endpoint Analysis in Phase II Clinical Trial of azficel-T for the TreThe last patient visit for primary endpoint analysis has been completed in its Phase II clinical trial of azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia. Fibrocell’s azficel-T has the potential to address the underlying cause of chronic dysphonia by using the patient’s own cells for localized treatment of the scarred vocal cords to improve voice quality.

Fibrocell’s Phase II study is a double-blind, randomized, placebo-controlled trial designed to test the safety and efficacy of azficel-T injections in subjects with chronic dysphonia caused by idiopathic vocal fold scarring or atrophy. Primary efficacy is being assessed at four months post last treatment on three different scales: Voice Handicap Index, Mucosal Wave Grade and GRBAS, or grade, roughness, breathiness, asthenia and strain. Fibrocell expects to report primary endpoint results for this Phase II trial in the second quarter of 2016.